Difference between revisions of "Meningioma"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "(NCT[0-9]{8}) Clinical Trial Registry" to "$1 $1")
m (Text replacement - "http://www.ncbi.nlm.nih.gov/pmc" to "https://www.ncbi.nlm.nih.gov/pmc")
 
(12 intermediate revisions by 2 users not shown)
Line 3: Line 3:
 
[[#top|Back to Top]]
 
[[#top|Back to Top]]
 
</div>
 
</div>
−
{| class="wikitable" style="text-align:center; width:50%;"
+
{{#lst:Editorial board transclusions|neuro}}
−
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor'''
+
''Are you looking for a regimen but can't find it here? For placebo or observational studies in this condition, please visit [[Meningioma - null regimens|this page]]. If you still can't find it, please let us know so we can add it!''
−
|-
 
−
|style="background-color:#F0F0F0"|[[File:SeemaNagpal.jpg|frameless|upright=0.3|center]]
 
−
|<big>[[User:Seemanagpal|Seema Nagpal, MD]]<br>Stanford University<br>Palo Alto, CA</big>
 
−
|-
 
−
|}
 
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
Line 18: Line 13:
  
 
=Guidelines=
 
=Guidelines=
 +
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
  
 
==EANO==
 
==EANO==
−
*'''2016:''' [https://doi.org/10.1016/S1470-2045(16)30321-7 EANO guidelines for the diagnosis and treatment of meningiomas] [https://pubmed.ncbi.nlm.nih.gov/27599143/ PubMed]  
+
*'''2016:''' Goldbrunner et al. [https://doi.org/10.1016/S1470-2045(16)30321-7 EANO guidelines for the diagnosis and treatment of meningiomas] [https://pubmed.ncbi.nlm.nih.gov/27599143/ PubMed]  
  
−
==[https://www.nccn.org/ NCCN]==
+
==ISRS==
−
*''NCCN does not have guidelines at this granular level; please go to the [[:Category:CNS cancers|Central Nervous System Cancers category page]].''
+
*'''2020:''' Marchetti et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7566438/ Stereotactic Radiosurgery for Intracranial Noncavernous Sinus Benign Meningioma: International Stereotactic Radiosurgery Society Systematic Review, Meta-Analysis and Practice Guideline] [https://pubmed.ncbi.nlm.nih.gov/32463867/ PubMed]
 +
*'''2018:''' Lee et al. [https://doi.org/10.1093/neuros/nyy009 Stereotactic Radiosurgery for Benign (World Health Organization Grade I) Cavernous Sinus Meningiomas-International Stereotactic Radiosurgery Society (ISRS) Practice Guideline: A Systematic Review] [https://pubmed.ncbi.nlm.nih.gov/29554317/ PubMed]
  
−
=Unresectable, all lines of therapy=
+
==NCCN==
−
==Placebo==
+
*''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1425 NCCN Guidelines - Central Nervous System Cancers].''
−
<div class="toccolours" style="background-color:#eeeeee">
 
−
===Regimen===
 
−
{| class="wikitable sortable" style="width: 100%; text-align:center;"
 
−
!style="width: 20%"|Study
 
−
!style="width: 20%"|Dates of enrollment
 
−
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
!style="width: 20%"|Comparator
 
−
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
−
|-
 
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669593/ Ji et al. 2015 (SWOG S9005)]
 
−
|1992-1998
 
−
|style="background-color:#1a9851"|Phase 3 (C)
 
−
|[[#Mifepristone_999|Mifepristone]]
 
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of FFS
 
−
|-
 
−
|}
 
−
''No active antineoplastic treatment.''
 
−
</div>
 
−
===References===
 
−
# '''SWOG S9005:''' Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015 Dec 1;33(34):4093-8. Epub 2015 Nov 2. [https://doi.org/10.1200/JCO.2015.61.6490 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669593/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26527781/ PubMed] [https://clinicaltrials.gov/study/NCT03015701 NCT03015701]
 
  
 
[[Category:Meningioma regimens]]
 
[[Category:Meningioma regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
 
[[Category:CNS cancers]]
 
[[Category:CNS cancers]]

Latest revision as of 12:10, 23 June 2024

Back to Top

Section editor
SeemaNagpal.jpg
 Seema Nagpal, MD
Stanford University
Palo Alto, CA, USA
LinkedIn

Are you looking for a regimen but can't find it here? For placebo or observational studies in this condition, please visit this page. If you still can't find it, please let us know so we can add it!

0 regimens on this page
0 variants on this page


Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

EANO

ISRS

NCCN

Retrieved from "https://hemonc.org/w/index.php?title=Meningioma&oldid=86344"